Valerian vs Hops for sleep — herbal sedatives, compared
The honest answer for both: subjective sleep quality improves modestly in some trials, objective polysomnography rarely changes much, and the better-evidenced product is the valerian-plus-hops combined extract used as Ze 91019. Single-ingredient hops has the thinner case; single-ingredient valerian has slightly more trial volume but inconsistent results. Both are reasonable to try, neither is in the same effect-size league as low-dose melatonin for circadian-misalignment insomnia or CBT-I for chronic insomnia.
Quick verdict
| Goal | Better choice | Why |
|---|---|---|
| Mild insomnia, subjective sleep quality | Combined valerian + hops (Ze 91019) | Most-studied combination has the most consistent positive trials. |
| Sleep onset latency | Valerian (modest) | Cochrane signal favors valerian for subjective sleep latency; effect small. |
| Anxiety + sleep co-presenting | Valerian-hops combo | Both have anxiolytic claims but trial evidence is modest; combo product is best-studied. |
| Discontinuation symptoms after long-term benzodiazepine use | Valerian-hops (limited trial signal) | Used as adjunctive in some trials of benzo tapering; not a substitute for proper supervised taper. |
| Generic "wind-down tea" | Either — neither is dramatically active at tea doses | Steam-extracted teas deliver much less of the relevant compounds than capsules. |
| Predictable next-day function | Either (mild edge to valerian-hops combo) | Both produce occasional next-morning grogginess; less common than with antihistamine sleep aids. |
How they actually work
Valerian (Valeriana officinalis) — GABAergic modulator
Valerian extracts contain valerenic acid, valerenol, and a range of iridoid valepotriates. The mechanism of action is most consistent with positive allosteric modulation of GABA-A receptors plus partial agonism at the A2a adenosine receptor — a profile that overlaps with the mild end of benzodiazepines without producing benzodiazepine-grade sedation. Onset is gradual (weeks for cumulative effect), unlike the immediate-onset profile of melatonin or antihistamines.
Hops (Humulus lupulus) — bitter-acid GABAergic plus melatonin-receptor activity
Hops contains alpha and beta bitter acids (humulones and lupulones), prenylated flavonoids (xanthohumol, 8-prenylnaringenin), and 2-methyl-3-buten-2-ol — a fragrance compound generated on storage with mild sedative activity in animals. Hops also shows in-vitro activity at melatonin MT1/MT2 receptors. The single-ingredient hops trial base is thin; most clinical evidence comes from valerian-hops combination products.
The Ze 91019 trials — the most-cited evidence
The Ze 91019 fixed-combination preparation (valerian 250 mg dry extract + hops 60 mg dry extract per tablet) has the most consistent trial base. Trials in adults with non-organic insomnia show modest improvements in subjective sleep latency and sleep quality versus placebo, with comparable safety. The combination outperforms valerian alone in some head-to-head trials, possibly because hops contributes the MT-receptor activity that valerian lacks. This is the empirical case for "combo over solo" with these herbs.
How they compare with melatonin
Low-dose melatonin (0.3–0.5 mg) at biologic dusk-shifted timing is the better-evidenced intervention for sleep phase delays and circadian misalignment — the population where most "valerian doesn't help" complaints originate. Melatonin and valerian work on different problems. If your issue is delayed sleep phase (you go to bed late, can't fall asleep, naturally wake late), melatonin's circadian effect is what you need, not herbal sedation.
Onset and consistency
Both herbs have inconsistent acute effects — a single dose may or may not produce noticeable sedation. The cleaner clinical signal comes from 2–4 weeks of consistent nightly dosing. Trial endpoints that improve are subjective sleep quality scales (Pittsburgh Sleep Quality Index, Insomnia Severity Index); polysomnography rarely shows large architectural changes.
Dose, form, and timing
Valerian (single-ingredient): 300–600 mg dry root extract (4:1 to 7:1 ratio) 30–60 minutes before bed. Tea is much less reliably dosed.
Hops (single-ingredient): 100–500 mg dry extract; standalone trial base is thin.
Valerian + Hops combo: 250 mg valerian + 60 mg hops dry extracts (Ze 91019 formula and similar) at bedtime.
Safety
Both herbs are generally well-tolerated. Occasional next-morning grogginess. Rare hepatotoxicity has been reported with valerian (case reports; pooled rate very low). Avoid combination with benzodiazepines, opioids, alcohol, and sedating antihistamines — additive sedation. Avoid in pregnancy and lactation due to insufficient safety data. Hops contains 8-prenylnaringenin, a potent phytoestrogen — avoid in estrogen-sensitive conditions. Valerian has odor that many users dislike; encapsulated forms minimize this.
What we'd actually buy
A valerian-hops combination product (Ze 91019 or generic equivalent) at the dose used in trials, taken 30–60 minutes before bed for 2–4 weeks. If sleep problems persist, escalate to clinician evaluation and CBT-I rather than stacking more herbs.
Sources
- Bent S, et al. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006;119(12):1005–1012. PMID: 17145239
- Koetter U, et al. A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytother Res. 2007;21(9):847–851. PMID: 17500966
- Fernández-San-Martín MI, et al. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11(6):505–511. PMID: 20347389
- Franco L, et al. The sedative effect of non-alcoholic beer in healthy female nurses. PLoS One. 2012;7(7):e37290. PMID: 22844485
- Salter S, Brownie S. Treating primary insomnia: the efficacy of valerian and hops. Aust Fam Physician. 2010;39(6):433–437. PMID: 20628685
- Shinjyo N, et al. Valerian root in treating sleep problems and associated disorders—a systematic review and meta-analysis. J Evid Based Integr Med. 2020;25:2515690X20967323. PMID: 33086877